Search for: "NOVARTIS AG"
Results 1 - 20 of 87
Sorted by Relevance | Sort by Date
21 Jan 6:02 am
Barrister Jane Lambert writes in her 500th post at her NIPC blog: This was a claim by Actavis for the revocation of a Novartis's European
patent for a preparation which released fluvastatin (a cholesterol inhibiting drug) gradually rather ... counterclaim came on before Mr Justice Warren and is reported at Actavis UK Ltd
v Novartis AG [2009] EWHC 41 (Ch) (16 January 2009) This case is important because it is one of the
first cases since Conor Medsystems Inc v Angiotech Pharmaceuticals Inc amd others ...
2 Apr 5:00 pm
CNCiv. y Com. Fed., sala I, 19/06/08, Novartis A.G. c. Laboratorios Richmond S.A.C.I.yF. Arraigo. Caso conectado con Suiza. Convención sobre
Procedimiento Civil La Haya 1954. Interpretación restrictiva. 2º instancia.‑ Buenos Aires, ... (conf. fs. 222, ptos. 2 y 3). 2. Tal como ha manifestado en este expediente la parte
actora (conf. fs. 194) el domicilio real de Novartis A.G. se encuentra en Suiza, que es uno de los países que junto con la República Argentina,
ratificaron la Convención de La Haya. ...
19 Jan 4:14 pm
24 Oct, 2008 12:32 am
... at Business Week: Mylan Inc. said Wednesday it has been accused of patent infringement by Novartis AG over Mylan's generic version of the Swiss company's Lescol capsules for treating high cholesterol. Pittsburgh-based Mylan said Novartis filed a lawsuit earlier this month in U.S. District Court in New Jersey accusing ... company filed an ANDA with the U.S. Food and Drug Administration
(FDA) in June. Novartis filed a lawsuit Oct. 10 in the U.S. District Court for the District of New Jersey ...
2 Aug, 2007 12:44 pm
The drug company Novartis AG will have to defend itself against sex-discrimination claims brought by
a group of female sales employees in a $100 million class-action lawsuit, a federal judge has ruled. The class action ... representatives, sales consultants, sales associates and some
district managers. In his order, the judge also granted a request to dismiss claims against Novartis Corp., the pharmaceutical unit's U.S.
parent. The lawsuit, which originally was filed in 2004, had alleged the Novartis ...
22 Sep, 2007 5:40 am
The HinduBusinessLine reports: Ranbaxy Laboratories has dropped its patent challenge of Novartis AG's
hypertension drug Diovan. The Gurgaon-based company has changed its Para IV application with the US Food and Drug Administration, ... ingredient of the hypertension drug. Following
which the Swiss company, filed a suit against Ranbaxy in August claiming infringement of its patent. Novartis is reported to have asked a
federal court in Newark, New Jersey, on Friday, Sept. 21, 2007, to drop the case. ...
7 Apr, 2008 9:32 pm
By Christopher P. Singer -- In April 7, 2008 press releases from Novartis AG and Alcon Inc., the
companies announced that Novartis has reached an agreement with Nestlé S.A. which provides Novartis
with the right to acquire majority ownership of Alcon Inc. Nestlé currently owns 77% of the outstanding shares...
28 Jan, 2007 7:40 pm
Despite pressure from non-governmental organizations, and public health groups around the world, Novartis AG has decided to go ahead with its legal challenge against the provisions of the Indian patent law specifically meant to restrict the scope of patentability
on drugs. Novartis' petition, which will be heard by a Division Bench at the Chennai [...]
30 Mar, 2007 5:36 pm
Article in the Wall Street Journal -- Novartis to Suspend U.S. Sales Of Zelnorm on FDA Request, by Anna Wilde Mathews and Jeanne Whalen. Here's
an excerpt:Novartis AG said it will suspend U.S. sales of Zelnorm, a drug for irritable-bowel...
5 Feb, 2008 9:55 pm
By Donald Zuhn -- Last week, Swiss drug maker Novartis AG agree to supply its cancer drug Glivec® at
no cost to patients in Thailand in exchange for the Thai government's agreement not to issue a compulsory license on Novartis' patent. Glivec®
(imatinib), which is sold as Gleevac® (imatinib mesylate)...
6 Dec, 2006 6:01 am
Savient Pharmaceuticals Inc. said a U.S. federal court (D NJ) granted a temporary restraining order [TRO] enjoining all sales of generic oxandrolone tablets by Novartis AG'S Sandoz Pharmaceuticals, and Upsher-Smith Laboratories. The order was given Dec. 4 in a Hatch-Waxman
lawsuit filed by Savient against Sandoz and Upsher-Smith for infringement of patents related to its oral anabolic steroid Oxandrin.
22 Apr, 2007 9:51 pm
By Donald Zuhn -- Last Thursday, Novartis AG announced that it had signed an exclusive license with
Antisoma PLC for the worldwide rights to the cancer therapeutic AS1404. AS1404 is a member of a class of compounds known as small molecule vascular disrupting agents (VDAs). VDAs, which
selectively disrupt established...
15 Feb, 2007 9:00 pm
... than its obligations under the International Trade Law, this crucial supply of medicines could be threatened," he said. Novartis has
reiterated that the company was denied a patent on its anti-cancer drug Glivec [Gleevec] in India because its laws ... Proposition 71 California Stem Cell Research and Cures Initiative.
New York: Analysis Group. Available: http://www.ag-inc.com/AnalysisGroup/uploadedFiles/News_and_Events/News/Proposition_71_report.pdf. Of
course, the Baker - Deal report has come under ...
5 Dec, 2008 5:31 am
... Mylan Pharmaceuticals, Inc. announced that they had settled their dispute with Novartis Pharmaceuticals Corp., Novartis Corp., and Novartis International AG over a generic version of
Novartis' Femara® tablets.According to the press release, Femara® tablets, which are ... treatment of breast cancer, had U.S. sales of about
$470 million for the 12 months ending September 30, 2008. Novartis initiated the dispute in June of 2006, when it sued Mylan following Mylan's
filing of an ANDA with a Paragraph ...
25 Apr, 2007 8:14 pm
By Jason Derry -- Cytos Biotechnology AG has granted a worldwide, exclusive license to Novartis to
develop, manufacture, and commercialize its therapeutic vaccine for nicotine addiction, CYT002-NicQb. The vaccine is currently in Phase II clinical development. Cytos may receive
upfront and milestone payments, as well as royalty payments, based on...
18 Nov 4:57 am
... Baristas) US: The Coinco strategy - what can go wrong with ownership of patents within a corporate enterprise - Novartis Pharm. Corp. v.
Teva Pharm. USA, Inc. (Property, intangible) US: How do you ... (Patent Docs) Myfortic7 (Mycophenolate) - US: Patent infringement suit filed in response to Paragraph IV certification -
Novartis AG et al. v. Apotex Inc. et al. (Patent Docs) Prandimet (Repaglinide and Metformin) - US:
Patent infringement suit filed in response to Paragraph IV certification: Novo ...
23 Jul 2:30 am
It was decided rather earlier this month, but the ruling of Mr Justice Kitchin in Novartis AG and
Cibavision AG v Johnson & Johnson Ltd and another [2009] EWHC 1671 (Pat) has taken a while to reach the top of the IPKat's must-blog pile.
356 ... Kat to read and, though he hates to admit it, even longer to get the hang of what it's all about. In brief, Novartis claimed that
J&J's Acuvue Oasys products infringed its European patent for extended-wear silicone ...
8 Nov 9:28 pm
... will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Novartis AG et al. v. Apotex Inc. et al. 1:09-cv-06950; filed November 4, 2009 in the Northern District of Illinois
• Plaintiffs: Novartis AG; Novartis Pharmaceuticals Corp. •
Defendants: Apotex Inc.; Apotex Corp. Infringement of U.S. Patent Nos. 6,025,391 ("Enteric-coated Pharmaceutical Compositions of Mycophenolate," issued February 15, 2000), 6, ...
25 Sep, 2007 3:00 pm
... active chelating agent that removes excess iron in patients undergoing regular blood transfusions. Marketed in the U.S. by Novartis
AG (NVS), Exjade was approved by the FDA for sale in 1995. Adverse drug reaction reports associated with Exjade ... out its September 2007
Exjade update article, the FDA said that additional studies are being conducted in order for the agency and Novartis to "determine the
longer-term benefits and risks of [Exjade (deferasirox)]." Of course, we will continue to monitor ...
23 Nov, 2007 9:00 am
... 's non-infringement and invalidity counterclaims dismissed: (IPLaw360), Fuzeon (Enfuvirtide) - Novartis sues Roche for patent infringement:
(IPLaw360), Teva's aggressive generic plans ... IP), Thai Public Health Minister Mongkol Na Songkhla today said that Novartis' 'may' provide
Thailand with free cancer medicine [Imatinib/ Gleevec] if the country ... Business Method Patents in the USA: (IPLaw360), (Peter Zura), CooperVision Inc. and Novartis AG unit Ciba Vision Corp. settle patent infringement suit over ...
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!